lenalidomide has been researched along with gemcitabine in 14 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (gemcitabine) | Trials (gemcitabine) | Recent Studies (post-2010) (gemcitabine) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 12,523 | 3,208 | 6,923 |
| Protein | Taxonomy | lenalidomide (IC50) | gemcitabine (IC50) |
|---|---|---|---|
| Chain A, DEOXYNUCLEOSIDE KINASE | Drosophila melanogaster (fruit fly) | 0.76 | |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | 0.19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dalgleish, AG; Liu, WM; Nizar, S | 1 |
| Dougherty, DW; Friedberg, JW | 1 |
| Alba, L; Antinori, A; Bibas, M; Del Nonno, F; Grisetti, S; Picchi, G | 1 |
| Dalgleish, AG; Gravett, AM; Liu, WM | 1 |
| Barlett, B; Dalgleish, AG; Fryer, RA; Galustian, C | 1 |
| Bocchia, M; Cencini, E; Defina, M; Fabbri, A; Fontanelli, G; Gozzetti, A; Mazzei, MA; Pietrini, A; Volterrani, L | 1 |
| Arkenau, HT; Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, GT; Lane, CM; Rubin, MS; Spigel, DR; Waterhouse, D | 1 |
| Agarwal, N; Apolo, AB; Galsky, MD; Gimpel-Tetra, K; Godbold, JH; Lee, KM; Lowe, N; Oh, WK; Poole, A; Soto, R; Tsao, CK | 1 |
| Liljefors, M; Rossmann, E; Ullenhag, GJ | 1 |
| Duvic, M | 1 |
| Aiba, K; Hayashi, K; Homma, S; Ito, M; Kamata, Y; Kan, S; Nagasaki, E | 1 |
| Broberg, M; Liljefors, M; Mellstedt, H; Mozaffari, F; Ullenhag, GJ | 1 |
2 review(s) available for lenalidomide and gemcitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Lenalidomide; Nitrogen Mustard Compounds; Rituximab; Thalidomide; Vinblastine; Vinorelbine | 2010 |
4 trial(s) available for lenalidomide and gemcitabine
| Article | Year |
|---|---|
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Rate; Thalidomide | 2013 |
Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Lenalidomide; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Thalidomide; Urothelium | 2014 |
A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Injections, Intravenous; Lenalidomide; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreas; Pancreatic Neoplasms; Thalidomide | 2015 |
Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lenalidomide; Leukocytes, Mononuclear; Male; Middle Aged; Pancreatic Neoplasms; Thalidomide | 2017 |
8 other study(ies) available for lenalidomide and gemcitabine
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lenalidomide; Pancreatic Neoplasms; Thalidomide | 2010 |
Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Boronic Acids; Bortezomib; Cytarabine; Deoxycytidine; Dexamethasone; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Lenalidomide; Lymphoma, Large-Cell, Immunoblastic; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Pyrazines; Recombinant Proteins; Thalidomide; Young Adult | 2010 |
The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies.
Topics: Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Blotting, Western; Breast Neoplasms; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Lenalidomide; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Thalidomide; Tumor Cells, Cultured | 2011 |
Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Butadienes; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Lenalidomide; Nitriles; Pancreatic Neoplasms; Phosphorylation; Thalidomide; Tumor Cells, Cultured | 2011 |
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Drugs, Investigational; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Organoplatinum Compounds; Polyethylene Glycols; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vinblastine; Vinorelbine | 2013 |
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Deoxycytidine; Depsipeptides; Diphtheria Toxin; Disease Progression; Doxorubicin; Electrons; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Incidence; Interleukin-2; Lenalidomide; Lymphoma, T-Cell; Mycosis Fungoides; Pentostatin; Photopheresis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Retinoids; Sezary Syndrome; Stem Cell Transplantation; Thalidomide; United States; Vorinostat | 2015 |
Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.
Topics: Antigens, CD20; Azacitidine; Cell Line, Tumor; Complement System Proteins; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Rituximab; Thalidomide; Up-Regulation | 2016 |